957855-56-0

Basic information

• Product Name: 2-fluoro-N-(1-methyl-4-piperidyl)-4-nitro-benzamide
• Synonyms: 2-fluoro-N-(1-methyl-4-piperidyl)-4-nitro-benzamide
• CAS NO: 957855-56-0
• Molecular Weight: 281.287
• Mol File: 957855-56-0.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 2-fluoro-N-(1-methyl-4-piperidyl)-4-nitro-benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-fluoro-N-(1-methyl-4-piperidyl)-4-nitro-benzamide(957855-56-0)
• EPA Substance Registry System: 2-fluoro-N-(1-methyl-4-piperidyl)-4-nitro-benzamide(957855-56-0)

Safety Data

• Hazardous Substances Data: 957855-56-0(Hazardous Substances Data)

Upstream product

• 41838-46-4 4-Amino-1-methylpiperidine 
• 403-24-7 2-fluoro-4-nitrobenzoic acid 

Downstream Products

• 957855-54-8 4-amino-2-fluoro-N-(1-methylpiperidin-4-yl)benzamide 
• 957855-51-5 4-[[(7R)-8-cyclopentyl-7-ethyl-5-methyl-6-oxo-7H-pteridin-2-yl]amino]-2-fluoro-N-(1-methyl-4-piperidyl)benzamide 

Relevant articles and documents

Design, synthesis, biological evaluation and molecular docking study of novel thieno[3,2-d]pyrimidine derivatives as potent FAK inhibitors

A series of 2,7-disubstituted-thieno[3,2-d]pyrimidine derivatives were designed, synthesized and evaluated as novel focal adhesion kinase (FAK) inhibitors. The novel 2,7-disubstituted-thieno[3,2-d]pyrimidine scaffold has been designed as a new kinase inhibitor platform that mimics the bioactive conformation of the well-known diaminopyrimidine motif. Most of the compounds potently suppressed the enzymatic activities of FAK and potently inhibited the proliferation of U-87MG, A-549 and MDA-MB-231 cancer cell lines. Among these derivatives, the optimized compound 26f potently inhibited the enzyme (IC50 = 28.2 nM) and displayed stronger potency than TAE-226 in U-87MG, A-549 and MDA-MB-231 cells, with IC50 values of 0.16, 0.27, and 0.19 μM, respectively. Compound 26f also exhibited relatively less cytotoxicity (IC50 = 3.32 μM) toward a normal human cell line, HK2. According to the flow cytometry results, compound 26f induced the apoptosis of MDA-MB-231 cells in a dose-dependent manner and effectively arrested MDA-MB-231 cells in G0/G1 phase. Further investigations revealed that compound 26f potently suppressed the migration of MDA-MB-231 cells. Collectively, these data support the further development of compound 26f as a lead compound for FAK-targeted anticancer drug discovery.

NOVEL COMPOUNDS

There is provided a compound of formula (I): processes for the manufacture thereof, pharmaceutical compositions thereof and uses in therapy.

DIHYDROPTERIDINE COMPOUNDS AS ANTI PROLIFERATIVE AGENTS

Compounds of formula (I), or optionally the pharmacologically acceptable acid addition salts thereof, and their use in the inhibition of PLK activity are described.